Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06892522 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

A Phase 1 study of Multiple Myeloma, sponsored by AbbVie.

Recruiting
Registry status
Phase 1
Development phase
440
Enrollment target
20
Study locations

NCT06892522 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 440 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06892522, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 1
Development phase
440 participants
Enrollment target
20
Study locations

Study Summary

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 4 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants will receive escalating doses of etentamig alone or in combination with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R). This will be followed by etentamig at the dose levels established during the escalation phases alone or in combination with DR, Kd, R. The participants can also receive daratumumab, lenalidomide and dexamethasone (DRd), R, or daratumumab, carfilzomib, and dexamethasone (DKd) as a comparator in the dose expansion phases. Around 440 adult participants with MM will be enrolled at approximately 50 sites worldwide In all substudies, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or in combination with DR, R or Kd, followed by IV infusions of etentamig at the dose levels established during the escalation phases alone or in combination with IV and oral DRd, DKd, or R. The study duration is approximately 130 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab
  • DRUG Etentamig

Study Locations (20)

North Carolina

  • University of North Carolina at Chapel Hill /ID# 274667 - Chapel Hill
  • Atrium Health Levine Cancer Institute /ID# 276193 - Charlotte
  • Atrium Health Wake Forest Baptist Medical Center /ID# 274847 - Winston-Salem

New South Wales

  • Coffs Harbour Health Campus /ID# 272010 - Coffs Harbour
  • Port Macquarie Base Hospital /ID# 275925 - Port Macquarie
  • Westmead Hospital /ID# 271880 - Westmead

Victoria

  • St Vincent's Hospital - Melbourne /ID# 276451 - Fitzroy
  • Peter MacCallum Cancer Centre /ID# 272024 - Melbourne

Other

  • Rambam Health Care Campus- Haifa /ID# 271364 - Haifa
  • Hadassah Medical Center-Hebrew University /ID# 271362 - Jerusalem

Colorado

  • Colorado Blood Cancer Institute /ID# 273129 - Denver

Florida

  • Moffitt Cancer Center /ID# 272628 - Tampa

Georgia

  • Winship Cancer Institute of Emory University /ID# 274830 - Atlanta

New York

  • Weill Cornell Medical College /ID# 272517 - New York

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2025-06-30
Est. Completion 2036-03
Phase Phase 1

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06892522

The ClinicalTrials.gov registry entry for NCT06892522 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (19% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT06892522 reports 20 study locations spanning 14 distinct geographic areas - top geographies include North Carolina, New South Wales, Victoria.

Frequently Asked Questions

What is clinical trial NCT06892522 about?

NCT06892522 is a clinical study titled "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib". Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed...

What is the current status of trial NCT06892522?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2025-06-30. Estimated completion is 2036-03.

What conditions does trial NCT06892522 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06892522?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Etentamig (DRUG).

Who is sponsoring clinical trial NCT06892522?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06892522 being conducted?

This trial has 20 study locations across Colorado, Florida, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.